Rapport Therapeutics, Inc. (RAPP) stock
RAPPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$23.76−1.06 (-4.27%)
Close on Nov 17, 2026Market cap $1.14BP/E –Yield –
Rapport Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Rapport Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$167.62M. For fiscal 2025 it was -$125.10M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$125.10M | – |
| FY2024 | Dec 31, 2024 | -$83.06M | – |
| FY2023 | Dec 31, 2023 | -$36.18M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$44.09M | – |
| Q2 FY2026 | Jun 30, 2026 | -$60.81M | – |
| Q1 FY2026 | Mar 31, 2026 | -$24.22M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.51M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.99M | – |
| Q2 FY2025 | Jun 30, 2025 | -$29.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -$27.11M | – |
| Q4 FY2024 | Dec 31, 2024 | -$23.52M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.64M | – |
| Q2 FY2024 | Jun 30, 2024 | -$20.80M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.09M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.79M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.56M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.63M | – |
See a number that looks wrong?